News Image

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials

Active Research Pipeline with Programs Progressing in Myotonic Dystrophy Type-1 (DM1) and Huntington’s Disease (HD)

Read more at globenewswire.com

DESIGN THERAPEUTICS INC

NASDAQ:DSGN (2/11/2025, 3:06:38 PM)

3.8

-0.46 (-10.8%)

DSGN Latest News and Analysis

ChartMill News Imagea day ago - ChartmillMonday's pre-market session: top gainers and losers

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Follow ChartMill for more